Key Dates

Related Announcements

PAR-22-047 - Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

Issued by

National Institute on Aging (NIA)

Purpose

This notice informs potential applicants of changes to Funding Opportunity Announcement (FOA) PAR-22-047, "Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)." Specifically, this notice corrects several missing headers their associated instructions.

The following sections under Part 2. Full Text of Announcement of PAR-22-047 have been modified:

Section IV. Application and Submission Information

The following headers and text have been added:

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.  

SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.  

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.  

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed. 

PHS Assignment Request Form

All instructions in the SF424 (R&R) Application Guide must be followed. 

The following text has been added under the "R&R or Modular Budget" header:

All instructions in the SF424 (R&R) Application Guide must be followed.

The following header has been added above the text that reads "When involving human subjects research...":

PHS Human Subjects and Clinical Trials Information

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Lorenzo M. Refolo, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-594-7576
Email: [email protected]